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High PDGFRA expression does not serve as an effec-
tive therapeutic target in ERG-deleted B-cell precur-
sor acute lymphoblastic leukemia
Several oncogenic aberrations of receptor tyrosine kinas-
es have been reported in B-cell precursor acute lymphoblas-
tic leukemia (BCP-ALL). Herein we describe a subgroup of
pediatric patients lacking common chromosomal aberra-
tions (“B-other”) but with high expression of platelet-
derived growth factor receptor alpha (PDGFRA).
Oncogenic fusions involving the tyrosine kinase domain of
PDGFRA are recurrent in eosinophilic leukemia and are
responsive to kinase inhibitors.1 One case with a FIP1L1-
PDGFRA fusion was reported in adult BCP-ALL.2 We,
therefore, tested for genomic aberrations underlying the
overexpression of PDGFRA and evaluated the inhibition of
PDGFRα as a treatment option in pediatric BCP-ALL. We
found that high PDGFRA expression was not caused by
structural aberrations of PDGFRA, was associated with
ERG deletions, and that the in vitro and ex vivo response to
PDGFRα inhibitors was limited in Nalm6 and primary
BCP-ALL cells, respectively.
Genetic aberrations that define distinct subtypes are
essential for diagnosis and risk evaluation of ALL. Gene
expression microarray analysis of 654 pediatric ALL cases
(data deposited in GSE87070) identified high PDGFRA
expression (2log expression probe-set 203131_at >5.9) in
26 of 574 BCP-ALL cases (4.5%). High PDGFRA expression
was found exclusively in cases belonging to the “B-other”
(n=22) and BCR-ABL1-like (n=4) subtypes, and was not
present in ETV6-RUNX1, high hyperdiploid (51-65 chro-
mosomes), TCF3-PBX1, BCR-ABL1 and MLL-rearranged
BCP-ALL subtypes or T-ALL. (Figure 1A). PGFRA expres-
sion was confirmed by quantitative reverse transcriptase
polymerase chain reaction analysis in 23 of 25 tested cases,
was maintained in xenograft-derived cells of a 
PDGFRA-high case, and also found in the BCP-ALL cell line
Nalm6 (Online Supplementary Figure S1). 
Since high PDGFRA expression was mainly found in the
“B-other” subtype, we analyzed clinical characteristics
within this group. Age, white blood cell count, gender, risk
stratification arm, and the frequency of relapse, death, and
non-response (together defining “events”) were not signifi-
cantly different between PDGFRA-high and -low “B-other”
cases (Table 1). However, cells from patients with high
PDGFRA expression levels were more sensitive to pred-
nisolone than were cells from patients with low PDGFRA
expression levels, as measured with an ex vivo MTT assay
previously described3 (P=0.03, see also Online
Supplementary Figure S2). Ex vivo sensitivity towards L-
asparaginase or vincristine was not different. 
Oncogenic fusions involving the tyrosine kinase domain
of PDGFRA are recurrent in adult myeloproliferative neo-
plasms, but have not been reported in pediatric BCP-ALL.
Using fusion gene-specific reverse transcriptase polymerase
chain reactions, we did not detect any of the six PDGFRA
fusions reported to date, which involve FIP1L1, STRN,
BCR, CDK5RAP2, ETV6, and KIF5B (see Online
Supplementary Table S1 and Online Supplementary Methods
for the primers).1,4-7
Novel translocations or other structural aberrations
affecting the PDGFRA locus may be responsible for high
PDGFRA expression. We performed fluorescence in situ
hybridization (FISH; Cytocell, Cambridge, UK) with probes
located upstream of FIP1L1, between FIP1L1 and PDGFRA,
and downstream of PDGFRA (Figure 1B). The cell line
EOL1 served as a positive control, revealing one wildtype
allele and two alleles with an interstitial deletion as report-
ed (DSMZ website July 2017, Online Supplementary Figure
S3). None of the 36 tested primary BCP-ALL samples and
cell lines with high or low PDGFRA expression showed
interstitial deletions between FIP1L1 and PDGFRA or split
FISH signals (Figure 1B and Online Supplementary Figure S3). 
We studied the PDGFRA locus at high resolution by tar-
geted locus amplification in 17 samples (Cergentis BV,
Utrecht, the Netherlands). This technique allows amplifica-
tion and sequencing of genomic regions that are in close
proximity to a region of interest and is described in more
detail in the Online Supplementary Methods. Two viewpoints
were selected in intron 2 and exon 15 of PDGFRA. In
EOL1, we confirmed an interstitial deletion on chromo-
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Table 1. Clinical characteristics of patients with “B-other“ B-cell precursor acute lymphoblastic leukemia with high PDGFRA expression.
PDGFRA high PDGFRA low 
Clinical feature Total Cases Frequency Total Cases Frequency P Odds ratio
(n) (n) (%) (n) (n) (%) (95%-CI)
Age ≥10 years 22 9 41% 90 30 33% 0.62
WBC ≥50/nl 22 4 18% 90 25 28% 0.43
Male 22 15 68% 90 50 56% 0.34
Treatment group HR 22 6 27% 87 39 45% 0.15
Relapse 22 2 9% 90 19 21% 0.24
Event 22 3 14% 90 26 29% 0.18
Death 22 2 9% 90 21 23% 0.24
Prednisolone LC50 ≥ 0.1 mg/mL 7 1 14% 26 18 69% 0.03 0.08 (0.002 -0.83)
Vincristine LC50 ≥ 0.39 mg/mL 7 4 57% 25 15 60% 1.00
L-asparaginase LC50 ≥ 0.033 mg/mL 7 6 86% 25 18 72% 0.64
“Total” indicates the number of cases for which data were available, ”cases” indicates the number of cases in which the respective feature was identified. Frequencies were
compared using the Fisher exact test and odds ratios are given with a 95% confidence interval (95% CI). P-values <0.05 are printed in bold. WBC: white blood cell count.
Treatment group HR: high risk treatment arm of the respective protocol. Event: relapse, non-response after consolidation phase, or death. LC50: 50% lethal concentration of
in vitro drug sensitivity testing as described previously.3
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Figure 1. Genomics of PDGFRA in pediatric B-cell precursor acute lymphoblastic
leukemia. (A) Gene expression of PDGFRA in the genetic subtypes of pediatric
BCP-ALL. Expression was measured on Affymetrix U133 plus 2.0 GeneChips using
two different probe sets. (B) Schematic overview and representative results of
interphase FISH probing the FIP1L1-PDGFRA locus in one case with high and one
case with low PDGFRA expression. Red: probe spanning the CHIC2 gene; green:
probes upstream of FIP1L1 and downstream of PDGFRA, respectively. Merge:
overlay of red and green signals, blue: DNA stained by DAPI. (C) Targeted locus
amplification performed from two viewpoints within the PDGFRA locus. Bars rep-
resent the mean coverage over a 10 kb sliding window plotted on the y-axis, while
chromosomal position is indicated on the x-axis. Coverage around the viewpoint
was capped for data visualization.7 Fourteen cases with high PDGFRA, one case
with low PDGFRA, and two cell lines were tested. In case of translocations or inter-
stitial deletions (e.g. causing the FIP1L1-PDGFRA fusion gene in EOL1), sequenc-
ing coverage drops steeply and rises again on a distant site. Samples marked by
roman numerals (patients I to V) were used in ex vivo cytotoxicity assays in Figure
2. (D) Frequencies of secondary aberrations detected by means of multiplex liga-
tion-dependent probe amplification and array comparative genomic hybridization
in “B-other” patients with high or low PDGFRA expression. chr21 gain: partial or
complete gain of chromosome 21, including germline trisomy. High CRLF2: high
expression of CRLF2 by gene expression array as described above. Frequencies
were compared using the Fisher exact test. *: P<0.05, **: P<0.01, ***: P<0.001.
For details see also Online Supplementary Methods.
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some 4 which rearranges FIP1L1 intron 12 to PDGFRA
exon 12 (Figure 1C). The coverage pattern and sequence
information obtained from Nalm6 and primary BCP-ALL
samples did not indicate genomic aberrations in PDGFRA. 
We compared recurrent copy number aberrations,
detected by multiplex ligation-dependent probe amplifica-
tion and array comparative genomic hybridization (as
reported by Boer et al.8), between PDGFRA-high and -low
“B-other” BCP-ALL cases (Figure 1D and Online
Supplementary Table S2). The frequency of deletions in
IKZF1, EBF1, RB1, BTG1, and TCF3 did not differ signifi-
cantly between “B-other” patients with high or low
PDGFRA expression. PAX5 and CDKN2A and/or B dele-
tions were rare in patients with high PDGFRA (P=0.01 and
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Figure 2. PDGFRα signaling and inhibition in pediatric B-cell precursor acute lymphoblastic leukemia cells. (A) Western blot for phosphorylated (Y762) and total
PDGFRα protein in the cell line Nalm-6. Cells were treated or not with 10 mM imatinib or 1 mM CP673451 and 10 ng/mL recombinant human PDGF-BB for 10
min. Arrow heads indicate the expected band. Total protein load was measured by staining for β-actin. It should also be noted that the closely related PDGFRB
is not expressed in cases with high PDGFRA expression. (B) and (C) Ex vivo sensitivity of cell lines and primary leukemic cells to PDGFRα inhibitors in an ex vivo
co-culture model. Cell lines (4 to 6 replicates) (B) and primary leukemic cells (C) were cultured with or without mesenchymal stromal cells (MSC) and exposed
to a range of imatinib conv (0.2 mM – 1.6 mM – 12.5 mM) or CP673451 (0.02 mM – 0.16 mM – 1.25 mM) for 4 days. Cell survival was analyzed by flow cytometry
and is depicted relative to the untreated control. Vehicle represents the respective vehicle control for imatinib (water) or CP673451 (DMSO) treated conditions.
For details see the Online Supplementary Methods. The results of individual samples are plotted and connected by lines. 
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P=0.03, respectively), and no loss of the entire chromo-
some-arm 9p was observed (P=0.02). No ETV6 deletion
(P=0.003), high CRLF2 expression (P=0.04), or chromo-
some 21 gain (P=0.006) was found in PDGFRA-high
patients. In contrast, 63% of patients with high PDGFRA
expression carried ERG deletions (10/16), compared with
0% of PDGFRA-low “B-other” cases (0/71, P<0.001). Vice
versa, all ERG-deleted cases expressed high levels of
PDGFRA (Online Supplementary Figure S4). A distinct gene
expression profile (referred to as R6 cluster) was described
as being characteristic for, but not limited to, ERG-deleted
cases.9 Recently, Lilljebjörn et al. reported strong overlap of
DUX4 rearrangements with ERG deletions and provided
evidence that the DUX4 rearrangement is causal for this
exclusive gene expression profile.10 In this newly described
BCP-ALL subtype, a truncated copy of the usually silenced
germline transcription factor DUX4 is inserted into an
actively transcribed region and aberrantly expressed.10,11
Zhang et al. showed that aberrant DUX4 induces the
expression of an alternative isoform of ERG, thereby direct-
ly linking the function of these two transcription factors.12
Importantly, not all DUX4-rearranged cases carried ERG
deletions, and they can arise at various points during leuke-
mogenesis of DUX4-rearranged leukemia.12,13 The identifi-
cation of DUX4 rearrangements at a genomic level is chal-
lenging because of varying integration sites, many repeats
in the genome, and high GC content. We were unable to
confirm DUX4 rearrangements in cases with high PDGFRA
expression, but strong evidence supports our conclusion:
Yasuda et al. have shown that Nalm6 carries a DUX4
rearrangement.11 In addition, in the extensive dataset on
DUX4-rearranged leukemia published by Zhang et al.12,
PDGFRA is highly expressed in DUX4-rearranged leukemia
and its transcription start site was directly bound by DUX4
(Online Supplementary Tables S3a and S14 of reference 12).
We therefore regard it as highly likely that the PDGFRA-
high cases represent this novel DUX4-rearranged subtype. 
These patients have a favorable outcome, but the risks of
chemotherapy still demand new therapeutic approaches.13
Because transcription factors are difficult to target with
small molecule inhibitors, PDGFRα inhibition could repre-
sent a treatment option. First, we confirmed protein
expression and activation of PDGFRα by western blotting
using Nalm6 cells. These cells were first starved and after-
wards briefly stimulated with 10 ng/mL recombinant
PDGFR-ligand PDGF-BB. Western blot analysis revealed
that the ligand activates the phosphorylation of PDGFRα at
position Y762 and reduces total PDGFRα levels (Figure 2A).
Exposure to the PDGFR inhibitors imatinib and CP673451
abrogated the ligand-induced activation of PDGFRα, and
prevented the phosphorylation of Y762. 
The sensitivity of BCP-ALL cells to PDGFRα inhibition
was evaluated in an ex vivo co-culture model including
bone marrow mesenchymal stromal cells (MSC). This
model has been previously shown to improve the survival
of primary BCP-ALL cells and also serves as a model of
microenvironment-mediated drug resistance.14 The cell line
EOL1 was highly sensitive to PDGFR inhibitors (imatinib
and CP673451) in culture with and without MSC, while
Nalm6 showed reduced viability only at the highest
inhibitor concentrations (Figure 2B). Primary BCP-ALL
samples with high PDGFRA expression were marginally
sensitive to imatinib, but not to CP673451, in mono-cul-
ture (Figure 2C, left side,) and in co-culture with MSC
(Figure 2C, right side). No cytotoxic effect of PDGFR
inhibitors was observed in cases with low PDGFRA expres-
sion (Figure 2C). For Nalm6 and three BCP-ALL samples
with sufficient material, the assay was repeated including
recombinant human PDGF-BB, but ligand exposure did not
sensitize to PDGFR inhibition (Online Supplementary Figure
S5). We, therefore, conclude that inhibition of PDGFRα sig-
naling with imatinib or CP673451 does not strongly reduce
viability in PDGFRA-expressing primary cells, nor in the
DUX4-rearranged PDGFRA-high expressing Nalm6 cell
line. This is in contrast to a strong reduction in survival
seen for the positive control, the FIP1L1-PDGFRA-
rearranged cell line EOL1. 
In summary, we have identified a group of BCP-ALL
cases with high expression of the receptor tyrosine kinase
PDGFRα. No genomic aberrations affecting the PDGFRA
locus were detected: fusion-specific polymerase chain reac-
tions to all known translocations were negative, FISH to
the PDGFRA locus showed no interstitial deletion or
translocation, and targeted locus amplification revealed no
structural aberrations. However, two-thirds of the cases
carried ERG deletions and, vice versa, all ERG-deleted cases
showed high PDGFRA expression. Therefore, high
PDGFRA expression likely characterizes the newly discov-
ered DUX4-rearranged subtype with frequent ERG dele-
tions.
Western blot experiments in the Nalm6 cell line demon-
strated ligand-dependent activation of PDGFRα which was
inhibited by imatinib and CP673451. Ex vivo exposure to
these inhibitors revealed that activation of PDGFRα is not
predictive for cytotoxicity in PDGFRA-high BCP-ALL cells.
The baseline clinical characteristics of PDGFRA-high cases
were not significantly different from those of “B-other”
cases with low PDGFRA expression, although the small
group size may have limited the analysis. Interestingly, we
found a marked ex vivo sensitivity towards prednisolone in
PDGFRA-high cases, in line with the good prognosis
reported for ERG-deleted/DUX4-rearranged leukemia.10,11,13 
In conclusion, despite high PDGFRA expression,
PDGFRα signaling was not essential to BCP-ALL cell sur-
vival ex vivo. Although in vivo data are warranted to corrob-
orate these results, we conclude that targets other than
PDGFRα should be explored for the cure of PDGFRA-high
BCP-ALL.
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